UA90457C2 - Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms - Google Patents
Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fmsInfo
- Publication number
- UA90457C2 UA90457C2 UAA200603154A UAA200603154A UA90457C2 UA 90457 C2 UA90457 C2 UA 90457C2 UA A200603154 A UAA200603154 A UA A200603154A UA A200603154 A UAA200603154 A UA A200603154A UA 90457 C2 UA90457 C2 UA 90457C2
- Authority
- UA
- Ukraine
- Prior art keywords
- csf
- human
- monoclonal antibody
- specifically binds
- human monoclonal
- Prior art date
Links
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 4
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/02—Marketing; Price estimation or determination; Fundraising
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/06—Buying, selling or leasing transactions
- G06Q30/0601—Electronic shopping [e-shopping]
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q40/00—Finance; Insurance; Tax strategies; Processing of corporate or income taxes
- G06Q40/04—Trading; Exchange, e.g. stocks, commodities, derivatives or currency exchange
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Information and communication technology [ICT] specially adapted for implementation of business processes of specific business sectors, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/12—Hotels or restaurants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Business, Economics & Management (AREA)
- Immunology (AREA)
- Accounting & Taxation (AREA)
- Finance (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Strategic Management (AREA)
- Physical Education & Sports Medicine (AREA)
- General Business, Economics & Management (AREA)
- General Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Physics & Mathematics (AREA)
- Marketing (AREA)
- Economics (AREA)
- Development Economics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Tourism & Hospitality (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
Abstract
Изобретение относится к человеческому моноклональному антителу или его антигенсвязующей части, которое специфически связывается с M-CSF человека и блокирует связывание M-CSF с c-fms. Изобретение также относится к применению данного антитела для изготовления фармацевтической композиции для лечения заболеваний, опосредованных M-CSF.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50216303P | 2003-09-10 | 2003-09-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
UA90457C2 true UA90457C2 (ru) | 2010-05-11 |
Family
ID=33300142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200603154A UA90457C2 (ru) | 2003-09-10 | 2004-09-09 | Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms |
Country Status (42)
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110091451A1 (en) * | 2002-11-15 | 2011-04-21 | Kavanaugh William M | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
GB0325836D0 (en) * | 2003-11-05 | 2003-12-10 | Celltech R&D Ltd | Biological products |
CA2552750C (en) * | 2004-01-07 | 2021-11-09 | Chiron Corporation | M-csf-specific monoclonal antibody and uses thereof |
CA2590671A1 (en) * | 2004-11-18 | 2006-05-26 | Imclone Systems Incorporated | Antibodies against vascular endothelial growth factor receptor-1 |
WO2006096489A2 (en) * | 2005-03-08 | 2006-09-14 | Pharmacia & Upjohn Company Llc | Anti-m-csf antibody compositions having reduced levels of endotoxin |
NZ560844A (en) | 2005-03-08 | 2008-08-29 | Pharmacia & Upjohn Co Llc | Anti-MAdCAM antibody compositions |
ES2538036T3 (es) * | 2005-07-28 | 2015-06-16 | Novartis Ag | Uso de anticuerpo a M-CSF |
EP2311876A3 (en) * | 2005-07-28 | 2011-04-27 | Novartis AG | M-CSF-specific monoclonal antibody and uses thereof |
JP4736037B2 (ja) * | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトgm−csfに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
TWI390034B (zh) * | 2006-04-06 | 2013-03-21 | Kyowa Hakko Kirin Co Ltd | Novel anti-CD98 antibody |
CL2007002225A1 (es) * | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
EA200970735A1 (ru) * | 2007-02-06 | 2010-02-26 | Рибовакс Байотекнолоджиз С.А. | Антитела, специфичные для вируса varicella zoster |
SI2188313T1 (en) * | 2007-08-21 | 2018-04-30 | Amgen, Inc. | HUMAN C-FMS ANTIGEN TRANSFER PROTEIN |
US20090104148A1 (en) * | 2007-09-18 | 2009-04-23 | Jay Gregory D | Treatment and prevention of joint disease |
PL2195017T3 (pl) | 2007-10-01 | 2015-03-31 | Bristol Myers Squibb Co | Ludzkie antyciała, które wiążą mezotelinę i ich zastosowania |
JP2011502266A (ja) * | 2007-10-31 | 2011-01-20 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Fms治療に対する応答を評価するバイオマーカー |
CN104072613A (zh) * | 2007-11-13 | 2014-10-01 | Evec股份有限公司 | 与hGM-CSF结合的单克隆抗体及包含它的药物组合物 |
EP2754671B1 (en) * | 2008-01-04 | 2016-12-21 | Baxalta Incorporated | Anti MIF antibodies |
CN101970496B (zh) * | 2008-03-14 | 2014-04-16 | 特朗斯吉有限公司 | 针对csf-1r的抗体 |
US8470977B2 (en) | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
JP2010043063A (ja) * | 2008-05-09 | 2010-02-25 | Agency For Science Technology & Research | 川崎病の診断及び治療 |
EP2406290B1 (en) | 2009-03-10 | 2017-07-05 | Baylor Research Institute | Antigen presenting cell targeted cancer vaccines |
ES2584956T3 (es) | 2009-03-10 | 2016-09-30 | Baylor Research Institute | Anticuerpos anti-CD40 y usos de los mismos |
CA2889453C (en) | 2009-03-20 | 2018-11-06 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
CU23736A1 (es) | 2009-05-04 | 2011-11-15 | Centro Inmunologia Molecular | Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso |
US8877199B2 (en) | 2009-05-15 | 2014-11-04 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | B cell surface reactive antibodies |
CN102574908B (zh) | 2009-08-27 | 2018-08-03 | 诺沃—诺迪斯克有限公司 | 组织因子向活化的血小板的靶向 |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
US20120208208A1 (en) * | 2009-10-30 | 2012-08-16 | Ni Yan G | Pcsk9 immunoassay |
CN106977603B (zh) * | 2010-05-04 | 2020-11-27 | 戊瑞治疗有限公司 | 结合csf1r的抗体 |
PL3789038T3 (pl) * | 2010-05-14 | 2023-01-23 | The Board Of Trustees Of The Leland Stanford Junior University | Humanizowane i chimeryczne przeciwciała monoklonalne wobec cd47 |
CA2803998A1 (en) | 2010-07-02 | 2012-01-05 | Medimmune, Llc | Antibody formulations |
CA2814780C (en) | 2010-09-22 | 2017-05-16 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
AU2015234335B2 (en) * | 2010-09-29 | 2017-09-28 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins |
IL290591B2 (en) | 2010-09-29 | 2024-08-01 | Seagen Inc | Antibody drug preparations (ADC) that bind to 191P4D12 proteins |
CN102603649B (zh) * | 2011-01-20 | 2016-05-25 | 赣南师范学院 | 一种以地巴唑为先导分子的荧光探针化合物及其制备方法 |
EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
CA2841013C (en) | 2011-07-18 | 2020-04-21 | Morphosys Ag | Use of c-fms antagonists |
CA2856149A1 (en) | 2011-11-08 | 2013-05-16 | Pfizer Inc. | Methods of treating inflammatory disorders using anti-m-csf antibodies |
US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
AR091069A1 (es) * | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
WO2014144817A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Inhibitory polypeptides specific to wnt inhibitors |
US9856316B2 (en) * | 2013-04-12 | 2018-01-02 | Morphosys Ag | Antibodies targeting M-CSF |
GB201315487D0 (en) * | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
MX2016002870A (es) | 2013-09-05 | 2017-02-23 | Amgen Inc | Moleculas que contienen fc que presentan perfiles de glicoforma predecibles, consistentes y reproducibles. |
CA2932819A1 (en) * | 2013-12-09 | 2015-06-18 | New York University | Compositions and methods for phagocyte delivery of anti-staphylococcal agents |
US10286058B2 (en) | 2014-01-13 | 2019-05-14 | Baylor Research Institute | Vaccines against HPV and HPV-related diseases |
CA2949237C (en) | 2014-05-16 | 2022-08-23 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
JP6964410B2 (ja) | 2014-06-23 | 2021-11-10 | ファイヴ プライム セラピューティクス インク | コロニー刺激因子1受容体(csf1r)に結合する抗体で疾患を治療する方法 |
TW201632202A (zh) | 2015-01-30 | 2016-09-16 | 諾華公司 | 乳癌之治療 |
CN112263677A (zh) | 2015-02-26 | 2021-01-26 | 默克专利股份公司 | 用于治疗癌症的pd-1/pd-l1抑制剂 |
IL256245B (en) | 2015-06-16 | 2022-09-01 | Merck Patent Gmbh | Treatments that combine a pd-l1 antagonist |
EA201891909A1 (ru) | 2016-03-11 | 2019-02-28 | Сколар Рок, Инк. | TGFβ1-СВЯЗЫВАЮЩИЕ ИММУНОГЛОБУЛИНЫ И ИХ ПРИМЕНЕНИЕ |
WO2018065938A1 (en) | 2016-10-06 | 2018-04-12 | Pfizer Inc. | Dosing regimen of avelumab for the treatment of cancer |
CR20190350A (es) * | 2017-01-06 | 2019-11-15 | Scholar Rock Inc | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS |
EP3596225A1 (en) | 2017-03-14 | 2020-01-22 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
US10610585B2 (en) | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
EP3694545A4 (en) | 2017-10-11 | 2021-12-01 | Board Of Regents, The University Of Texas System | HUMAN PD-L1 ANTIBODIES AND METHOD OF USING THEM |
EP3735270A1 (en) | 2018-01-05 | 2020-11-11 | Modernatx, Inc. | Polynucleotides encoding anti-chikungunya virus antibodies |
SG11202007518RA (en) | 2018-02-28 | 2020-09-29 | Pfizer | Il-15 variants and uses thereof |
JP7390301B2 (ja) | 2018-03-23 | 2023-12-01 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | ヒトpd-l2抗体およびその使用方法 |
US20210214445A1 (en) * | 2018-03-23 | 2021-07-15 | Board Of Regents, The University Of Texas System | Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor |
SG11202009216YA (en) | 2018-03-26 | 2020-10-29 | Amgen Inc | Total afucosylated glycoforms of antibodies produced in cell culture |
CN113286634A (zh) | 2018-05-23 | 2021-08-20 | 辉瑞公司 | 对gucy2c特异性的抗体及其用途 |
SG11202010580TA (en) | 2018-05-23 | 2020-12-30 | Pfizer | Antibodies specific for cd3 and uses thereof |
AU2019302642A1 (en) | 2018-07-10 | 2021-02-25 | Regeneron Pharmaceuticals, Inc. | Modifying binding molecules to minimize pre-existing interactions |
WO2020044252A1 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Dosage regimes for anti-m-csf antibodies and uses thereof |
US20220370606A1 (en) | 2018-12-21 | 2022-11-24 | Pfizer Inc. | Combination Treatments Of Cancer Comprising A TLR Agonist |
US11339159B2 (en) | 2019-07-17 | 2022-05-24 | Pfizer Inc. | Toll-like receptor agonists |
CA3152547A1 (en) | 2019-09-26 | 2021-04-01 | Amgen Inc. | Methods of producing antibody compositions |
CN115397853A (zh) | 2019-12-17 | 2022-11-25 | 辉瑞大药厂 | 对cd47、pd-l1具特异性的抗体及其用途 |
ES2969732T3 (es) | 2019-12-18 | 2024-05-22 | Pfizer | Régimen de tratamiento del cáncer una vez al día con un inhibidor de PRMT5 |
JP7481856B2 (ja) * | 2020-02-25 | 2024-05-13 | シスメックス株式会社 | 改変抗体及びその製造方法、並びに抗体の熱安定性を向上させる方法 |
US20240209061A1 (en) | 2020-03-09 | 2024-06-27 | Pfizer Inc. | Fusion proteins and uses thereof |
AU2021271318A1 (en) | 2020-05-13 | 2022-11-24 | Pfizer Inc. | Methods, therapies and uses for treating cancer |
EP4162257A1 (en) | 2020-06-04 | 2023-04-12 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
JP2023533793A (ja) | 2020-07-17 | 2023-08-04 | ファイザー・インク | 治療用抗体およびそれらの使用 |
CN116194105A (zh) | 2020-09-14 | 2023-05-30 | 辉瑞大药厂 | 治疗癌症的方法、疗法及用途 |
EP4229080A1 (en) | 2020-10-15 | 2023-08-23 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス,インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
WO2022153161A1 (en) | 2021-01-14 | 2022-07-21 | Pfizer Inc. | Treatment of cancer using a prmt5 inhibitor |
AU2022227029A1 (en) * | 2021-02-26 | 2023-08-31 | New York University | Compositions and methods comprising antibodies that bind to covalent peptide conjugates |
US20240279704A1 (en) | 2021-06-07 | 2024-08-22 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
AU2022361382A1 (en) | 2021-10-05 | 2024-03-28 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
WO2023218320A1 (en) | 2022-05-11 | 2023-11-16 | Pfizer Inc. | Anti-lymphotoxin beta receptor antibodies and methods of use thereof |
WO2023242769A1 (en) | 2022-06-17 | 2023-12-21 | Pfizer Inc. | Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof |
WO2024003773A1 (en) | 2022-07-01 | 2024-01-04 | Pfizer Inc. | 2,7-naphthyridine compounds as mastl inhibitors |
WO2024009191A1 (en) | 2022-07-05 | 2024-01-11 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
WO2024074977A1 (en) | 2022-10-04 | 2024-04-11 | Pfizer Inc. | Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds |
WO2024084364A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Compounds for the treatment of cancer |
WO2024105563A1 (en) | 2022-11-16 | 2024-05-23 | Pfizer Inc. | Substituted bicyclic pyridone derivatives |
Family Cites Families (244)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5531159A (en) | 1978-08-26 | 1980-03-05 | Sumitomo Metal Ind Ltd | Manufacture of high strength cold rolled steel plate for press working |
US4634665A (en) * | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US4504586A (en) * | 1983-02-03 | 1985-03-12 | Amgen | Hybridoma tumor cell lines and their monoclonal antibodies to human colony stimulating factor subclass number 1 |
US4740461A (en) * | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5573930A (en) * | 1985-02-05 | 1996-11-12 | Cetus Oncology Corporation | DNA encoding various forms of colony stimulating factor-1 |
US5837229A (en) | 1985-02-05 | 1998-11-17 | Chiron Corporation | Uses of recombinant colony stimulating factor-1 |
US5792450A (en) * | 1985-02-05 | 1998-08-11 | Chiron Corporation | Purified human CSF-1 |
US4847201A (en) * | 1985-02-05 | 1989-07-11 | Cetus Corporation | DNA encoding for CSF-1 and accompanying recombinant systems |
WO1986004607A1 (en) * | 1985-02-05 | 1986-08-14 | Cetus Corporation | Recombinant colony stimulating factor-1 |
US6117422A (en) * | 1985-02-05 | 2000-09-12 | Chiron Corporation | N∇2-CSF-1(long form) and carboxy truncated fragments thereof |
JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4868119A (en) * | 1986-12-11 | 1989-09-19 | Genetics Institute, Inc. | Hematopoietic growth factors |
HU212277B (en) * | 1986-05-06 | 1996-04-29 | Genetics Inst | Process for producing m-csf |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
GB8624899D0 (en) | 1986-10-17 | 1986-11-19 | Sandoz Ltd | Monoclonal antibodies |
US4912040A (en) * | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US4929700A (en) * | 1987-04-16 | 1990-05-29 | Cetus Corporation | Production of purified, biologically active, bacterially produced recombinant human CSF-1 |
CA1339757C (en) * | 1987-04-16 | 1998-03-17 | Robert F. Halenbeck | Production of purified biologically active, bacterially produced recombinant human csf-1 |
US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US4929455A (en) * | 1988-07-07 | 1990-05-29 | Mallinckrodt, Inc. | Flour-based pot pie crusts with improved texture |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
US5175384A (en) * | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
ATE141290T1 (de) * | 1989-02-10 | 1996-08-15 | Cetus Oncology Corp | M-csf-monoklonale antikörper, die ein neutralisierendes konformationales epitop erkennen |
JPH04503815A (ja) | 1989-07-14 | 1992-07-09 | シェリング・コーポレーション | カルボキシル末端から誘導されたgm―csfのアンタゴニスト |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
JPH05503098A (ja) * | 1989-12-15 | 1993-05-27 | カイロン コーポレイション | セプシスの処理のためのサイトカイン抗体 |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) * | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
JPH06508511A (ja) | 1990-07-10 | 1994-09-29 | ケンブリッジ アンティボディー テクノロジー リミティド | 特異的な結合ペアーの構成員の製造方法 |
US5789650A (en) * | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
EP0814159B1 (en) * | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
US6300129B1 (en) * | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) * | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6255458B1 (en) * | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5661016A (en) * | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0546091B1 (en) | 1990-08-29 | 2007-01-24 | Pharming Intellectual Property BV | Homologous recombination in mammalian cells |
US7041871B1 (en) * | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US7084260B1 (en) * | 1996-10-10 | 2006-08-01 | Genpharm International, Inc. | High affinity human antibodies and human antibodies against human antigens |
DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
CA2060741A1 (en) | 1991-02-11 | 1992-08-12 | Robert S. Greenfield | Gm-csf inhibiting oligopeptides |
EP0575485A1 (en) | 1991-03-01 | 1993-12-29 | Dyax Corp. | Process for the development of binding mini-proteins |
JP3672306B2 (ja) | 1991-04-10 | 2005-07-20 | ザ スクリップス リサーチ インスティテュート | ファージミドを使用するヘテロ二量体受容体ライブラリー |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
DE69229477T2 (de) | 1991-09-23 | 1999-12-09 | Cambridge Antibody Technology Ltd., Melbourn | Methoden zur Herstellung humanisierter Antikörper |
JPH0595794A (ja) * | 1991-10-04 | 1993-04-20 | Otsuka Pharmaceut Co Ltd | ヒトm−csf抗体及びヒトm−csfの測定法 |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
JPH08503121A (ja) | 1991-12-10 | 1996-04-09 | デイナ・フアーバー・キヤンサー・インステイテユート | 中和反応性ヒト抗−gp120組換え抗体、それをコードするdnaおよびその使用 |
JPH067189A (ja) | 1991-12-17 | 1994-01-18 | Morinaga Milk Ind Co Ltd | ヒトM−CSF β型ダイマ−に特異性を有するモノクロ− ナル抗体と、この抗体を産生するハイブリドーマ、お よびこの抗体の利用 |
DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
EP0668914B1 (en) * | 1992-06-09 | 2000-08-16 | Chiron Corporation | Crystallization of m-csf |
EP0652950B1 (en) | 1992-07-24 | 2007-12-19 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
JP3714683B2 (ja) * | 1992-07-30 | 2005-11-09 | 生化学工業株式会社 | 抗リウマチ剤 |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
JPH06194367A (ja) | 1992-12-25 | 1994-07-15 | Morinaga Milk Ind Co Ltd | リウマチ疾患の診断方法 |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
JP3801196B2 (ja) * | 1993-03-09 | 2006-07-26 | ジェンザイム・コーポレイション | 乳からの対象化合物の単離 |
JPH06319584A (ja) | 1993-05-07 | 1994-11-22 | Morinaga Milk Ind Co Ltd | 抗m−csfモノクロ−ナル抗体と、この抗体を産生 するハイブリド−マ |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
WO1995029690A1 (en) * | 1994-04-29 | 1995-11-09 | The Trustees Of The University Of Pennsylvania | Biologically active peptides and methods of identifying the same |
US5643763A (en) * | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
US6046037A (en) * | 1994-12-30 | 2000-04-04 | Hiatt; Andrew C. | Method for producing immunoglobulins containing protection proteins in plants and their use |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
US6091001A (en) * | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
CA2218503C (en) * | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
EP0826034A4 (en) | 1995-04-21 | 2002-06-19 | Cell Genesys Inc | PRODUCTION OF LARGE GENOMIC DNA DELETIONS |
ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
PT780386E (pt) | 1995-12-20 | 2003-02-28 | Hoffmann La Roche | Inibidores de metaloprotease de matriz |
NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
US5714352A (en) * | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
EP0912572B1 (en) | 1996-07-13 | 2003-01-15 | Glaxo Group Limited | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
PT912559E (pt) | 1996-07-13 | 2003-03-31 | Glaxo Group Ltd | Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
NZ333303A (en) | 1996-07-18 | 2000-06-23 | Lawrence Alan Reiter | Phosphinate based inhibitors of matrix metalloproteases |
BR9711223A (pt) | 1996-08-23 | 1999-08-17 | Pfizer | Derivados de cido arilsulfonilamino-hidrox mico |
ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
US6255455B1 (en) * | 1996-10-11 | 2001-07-03 | The Trustees Of The University Of Pennsylvania | Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof |
AU5702298A (en) * | 1996-12-03 | 1998-06-29 | Abgenix, Inc. | Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom |
EP0950059B1 (en) | 1997-01-06 | 2004-08-04 | Pfizer Inc. | Cyclic sulfone derivatives |
IL131042A (en) | 1997-02-03 | 2004-07-25 | Pfizer Prod Inc | Derivatives of arylsulfonamic acid hydroxyamic acid and medicinal preparations containing them |
EP0966438A1 (en) | 1997-02-07 | 1999-12-29 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
HUP0000657A3 (en) | 1997-02-11 | 2000-10-30 | Pfizer | N-arylsulfonyl-piperidine, -morpholine hydroxamic acid derivatives and pharmaceutical compositions containing them |
JP2002508656A (ja) | 1997-03-12 | 2002-03-19 | スミスクライン・ビーチャム・コーポレイション | 抗−アルファベータ3ヒト化モノクローナル抗体 |
RU2238949C2 (ru) * | 1997-04-15 | 2004-10-27 | Санкио Компани Лимитед | Белок, специфически связывающийся с ингибирующим остеокластогенез фактором (ocif) (варианты), днк его кодирующая (варианты), днк в качестве зонда (варианты), способ получения белка (варианты), способ скрининга вещества (варианты), антитело (варианты), способ получения поликлонального антитела, гибридома (варианты), способ получения моноклонального антитела, способ измерения ocif-связывающего белка, фармацевтическая композиция (варианты) и лекарственное средство (варианты) |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
EP0984930B1 (en) | 1997-05-07 | 2005-04-06 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
DE69833755T2 (de) | 1997-05-21 | 2006-12-28 | Biovation Ltd. | Verfahren zur herstellung von nicht-immunogenen proteinen |
JP2002501532A (ja) | 1997-05-30 | 2002-01-15 | メルク エンド カンパニー インコーポレーテッド | 新規血管形成阻害薬 |
ES2216293T3 (es) | 1997-08-08 | 2004-10-16 | Pfizer Products Inc. | Derivados de acido ariloxiarilsulfonilamino-hidroxamico. |
US6294532B1 (en) | 1997-08-22 | 2001-09-25 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
WO1999016755A1 (en) | 1997-09-26 | 1999-04-08 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
ID23978A (id) | 1997-11-11 | 2000-06-14 | Pfizer Prod Inc | Turunan-turunan tienopirimidin dan tienopiridin yang berguna sebagai zat-zat anti kangker |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
AU2978899A (en) | 1998-03-03 | 1999-09-20 | Abgenix, Inc. | Cd147 binding molecules as therapeutics |
JP4462654B2 (ja) | 1998-03-26 | 2010-05-12 | ソニー株式会社 | 映像素材選択装置及び映像素材選択方法 |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
CO5031249A1 (es) | 1998-05-29 | 2001-04-27 | Sugen Inc | Pirrol substituido-2-indolinonas inhibidoras de proteinci-nasas |
UA60365C2 (ru) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Производные изотиазола, способ их получения, фармацевтическая композиция и способ лечения гиперпролиферативного заболевания у млекопитающего |
AUPP525198A0 (en) | 1998-08-13 | 1998-09-03 | Medvet Science Pty. Ltd. | Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof |
CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
EP1004578B1 (en) | 1998-11-05 | 2004-02-25 | Pfizer Products Inc. | 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives |
CN1202128C (zh) | 1998-12-08 | 2005-05-18 | 拜奥威神有限公司 | 修饰蛋白的免疫原性 |
WO2000035956A1 (fr) * | 1998-12-16 | 2000-06-22 | Kyowa Hakko Kogyo Co., Ltd. | Anticorps monoclonal anti-vegf humain |
PT2112166T (pt) * | 1998-12-23 | 2019-01-30 | Pfizer | Anticorpos monoclonais humanos contra ctla-4 |
UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
JP3270834B2 (ja) * | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
US6471429B1 (en) * | 1999-01-29 | 2002-10-29 | Canon Kabushiki Kaisha | Sheet processing apparatus for discharging sheets in a bundle |
AU5761900A (en) | 1999-06-30 | 2001-01-31 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Human monoclonal antibodies to hiv-1 envelope glycoprotein gp120 |
KR100942863B1 (ko) | 1999-08-24 | 2010-02-17 | 메다렉스, 인코포레이티드 | 인간 씨티엘에이-4 항체 및 그의 용도 |
US7135287B1 (en) | 1999-10-02 | 2006-11-14 | Biosite, Inc. | Human antibodies |
US6794132B2 (en) | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
AU1759501A (en) | 1999-11-08 | 2001-06-06 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Method of treating a viral infection using antagonists of macrophage colony stimulating factor |
US6517529B1 (en) * | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
US6680209B1 (en) | 1999-12-06 | 2004-01-20 | Biosite, Incorporated | Human antibodies as diagnostic reagents |
EP1285084A1 (en) | 2000-01-25 | 2003-02-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
US20030232054A1 (en) | 2000-01-25 | 2003-12-18 | Tang Y. Tom | Novel nucleic acids and polypeptides |
US7108852B2 (en) * | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
US20030059427A1 (en) | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
EP2292665B1 (en) * | 2000-05-26 | 2015-07-08 | Immunex Corporation | Use of interleukin-4 antibodies and compositions thereof |
US7879328B2 (en) * | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
WO2002002641A1 (en) | 2000-06-16 | 2002-01-10 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to blys |
US20040253242A1 (en) | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
WO2002059340A1 (en) | 2001-01-26 | 2002-08-01 | The Scripps Research Institute | Immunopolypeptides to hepatitis c virus |
EP1370588A2 (en) | 2001-02-12 | 2003-12-17 | Medarex, Inc. | Human monoclonal antibodies to fc alpha receptor (cd89) |
US20020146753A1 (en) * | 2001-04-06 | 2002-10-10 | Henrik Ditzel | Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease |
JP4025881B2 (ja) | 2001-04-27 | 2007-12-26 | キリンファーマ株式会社 | 抗cd40モノクローナル抗体 |
DK1391464T3 (da) * | 2001-04-27 | 2008-01-14 | Kirin Pharma Kk | Anti-CD40 monoklonalt antistof |
US7115717B2 (en) * | 2001-05-18 | 2006-10-03 | Kirin Beer Kabushiki Kaisha | Anti-TRAIL-R antibodies |
JP2005168497A (ja) | 2001-05-18 | 2005-06-30 | Kirin Brewery Co Ltd | 抗trail−r抗体およびその用途 |
FI112501B (fi) | 2001-05-18 | 2003-12-15 | Valtion Teknillinen | Heveiiniä sitovat monoklonaaliset vasta-aineet |
AU2002316251A1 (en) | 2001-06-18 | 2003-01-02 | Rosetta Inpharmatics, Inc. | Diagnosis and prognosis of breast cancer patients |
US7171311B2 (en) | 2001-06-18 | 2007-01-30 | Rosetta Inpharmatics Llc | Methods of assigning treatment to breast cancer patients |
EP1429143A4 (en) | 2001-08-22 | 2006-04-12 | Inst Antibodies Co Ltd | SELECTION PROCEDURE FOR BINDING MOLECULES |
JP3665324B2 (ja) | 2001-10-15 | 2005-06-29 | 麒麟麦酒株式会社 | 抗hla−dr抗体 |
JP3729841B2 (ja) | 2001-10-15 | 2005-12-21 | 麒麟麦酒株式会社 | 抗hla−dr抗体の利用 |
CA2467521A1 (en) | 2001-11-16 | 2003-07-10 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to blys |
AU2002351208A1 (en) | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Antibodies against carbonic anhydrase IX (CA IX) tumor antigen |
AU2002357060A1 (en) | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
EP1322146A1 (en) | 2001-12-18 | 2003-06-25 | Phoenix Precision Technology Corporation | Method of electroplating solder bumps on an organic circuit board |
EP1471938A4 (en) | 2002-01-09 | 2008-03-05 | Medarex Inc | HUMAN MONOCLONAL ANTIBODIES AGAINST CD30 |
WO2003070752A2 (en) | 2002-02-20 | 2003-08-28 | Dyax Corporation | Mhc-peptide complex binding ligands |
JP2005520523A (ja) | 2002-03-21 | 2005-07-14 | イーライ・リリー・アンド・カンパニー | アンタゴニスト的抗hFasリガントヒト抗体およびそのフラグメント |
MXPA04010432A (es) | 2002-04-23 | 2005-05-27 | Scripps Research Inst | Expresion de polipeptidos en cloroplastos, y composiciones y metodos para expresar los mismos. |
US8586538B2 (en) | 2002-04-29 | 2013-11-19 | Stichting Sanquin Bloedvoorziening | Method of treating a patient suffering from a bleeding disorder comprising administering an antibody against the A3-C1 of FVIII |
US20040110933A1 (en) | 2002-09-13 | 2004-06-10 | Dyax Corporation | CD44-binding ligands |
US7396913B2 (en) * | 2002-10-14 | 2008-07-08 | Abbott Laboratories | Erythropoietin receptor binding antibodies |
TWI320716B (en) | 2002-10-14 | 2010-02-21 | Abbott Lab | Erythropoietin receptor binding antibodies |
EP2287192B1 (en) * | 2002-11-15 | 2015-08-26 | Novartis Vaccines and Diagnostics, Inc. | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
KR101329843B1 (ko) | 2002-11-15 | 2013-11-14 | 젠맵 에이/에스 | Cd25에 대한 인간 모노클로날 항체 |
AR042145A1 (es) | 2002-11-27 | 2005-06-08 | Dow Agrociences Llc | Produccion de inmunoglobulinas en plantas con una fucocilacion reducida |
US20050013809A1 (en) | 2002-12-02 | 2005-01-20 | Owens Samuel M. | Antibodies against drugs of abuse |
EP1578947A4 (en) | 2002-12-02 | 2006-12-06 | Abgenix Inc | ANTIBODIES AGAINST A2 PHOSPHOLIPASE AND USES |
WO2005035732A2 (en) * | 2003-02-19 | 2005-04-21 | Dyax Corporation | Papp-a ligands |
AU2004224390A1 (en) * | 2003-03-19 | 2004-10-07 | Abgenix, Inc. | Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof |
AU2004236263A1 (en) | 2003-05-06 | 2004-11-18 | Albert Einstein College Of Medicine Of Yeshiva University | Compositions and methods for treatment of cryptococcosis |
EP1627062A1 (en) | 2003-05-14 | 2006-02-22 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
AU2004270103B2 (en) | 2003-05-21 | 2012-02-23 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies against Bacillusanthracis protective antigen |
WO2004108078A2 (en) | 2003-06-02 | 2004-12-16 | Alexion Pharmaceuticals Inc. | Rationally designed antibodies |
SI1648509T1 (sl) | 2003-07-15 | 2012-12-31 | Amgen Inc. | Humana protitelesa, ki nevtralizirajo anti-ngf, kot selektivni inhibitorji poti nfg |
RU2377252C2 (ru) | 2003-07-22 | 2009-12-27 | Шеринг Акциенгезельшафт | Rg1 антитела и их применение |
HN2004000285A (es) * | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
AU2004266242A1 (en) | 2003-08-12 | 2005-03-03 | Dyax Corp. | Tie1-binding ligands |
CA2535859A1 (en) | 2003-08-14 | 2005-03-03 | Dyax Corp. | Endotheliase-2 ligands |
AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
US8119340B2 (en) | 2003-10-08 | 2012-02-21 | The Feinstein Institute For Medical Research | Methods and compositions for diagnosis and treatment of B cell chronic lymphocytic leukemia |
ATE548388T1 (de) | 2003-11-07 | 2012-03-15 | Immunex Corp | An den interleukin-4-rezeptor bindende antikörper |
CN1902228A (zh) | 2003-11-07 | 2007-01-24 | 安姆根有限公司 | 猴免疫球蛋白序列 |
JP4870348B2 (ja) | 2003-12-04 | 2012-02-08 | 株式会社ペルセウスプロテオミクス | 細胞表面抗原に対する抗体取得とその抗原同定 |
PL1691837T3 (pl) | 2003-12-10 | 2012-11-30 | Squibb & Sons Llc | IP-10 przeciwciała i ich zastosowanie |
EP1711207B1 (en) | 2003-12-10 | 2012-11-28 | Medarex, Inc. | Interferon alpha antibodies and their uses |
ES2378767T3 (es) | 2003-12-23 | 2012-04-17 | Crucell Holland B.V. | Molécula de unión humana contra CD1a |
CA2552750C (en) | 2004-01-07 | 2021-11-09 | Chiron Corporation | M-csf-specific monoclonal antibody and uses thereof |
RS51908B (en) | 2004-02-06 | 2012-02-29 | University Of Massachusetts | CLOSTRIDIUM DIFFICILE TOXIN ANTIBODIES AND THEIR USES |
US7271245B2 (en) | 2004-02-13 | 2007-09-18 | The Scripps Research Institute | Methods and compositions for inhibition of metastasis |
WO2005086713A2 (en) | 2004-03-04 | 2005-09-22 | Kirin Brewery Co., Ltd. | Role of human endothelial precursor cells and vascular pericytes tumor in angiogenesis |
CA2564989C (en) | 2004-03-19 | 2014-05-27 | Amgen, Inc. | Reducing the risk of human and anti-human antibodies through v gene manipulation |
RU2368622C2 (ru) * | 2004-04-13 | 2009-09-27 | Ф.Хоффманн-Ля Рош Аг | Антитела к р-селектину |
WO2005109266A1 (en) | 2004-05-07 | 2005-11-17 | Snap-On Incorporated | Tool monitoring system |
CA2572961C (en) | 2004-07-06 | 2016-08-16 | Bioren, Inc. | Universal antibody libraries |
WO2006020258A2 (en) | 2004-07-17 | 2006-02-23 | Imclone Systems Incorporated | Novel tetravalent bispecific antibody |
EP1967529A1 (en) | 2004-07-20 | 2008-09-10 | Symphogen A/S | Anti-rhesus D recombinant polyclonal antibody and methods of manufacture |
EP1807451A2 (en) | 2004-08-03 | 2007-07-18 | Dyax Corporation | Hk1-binding proteins |
WO2006017759A2 (en) | 2004-08-05 | 2006-02-16 | Kirin Brewery Co., Ltd. | Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof |
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
AU2005272848A1 (en) | 2004-08-12 | 2006-02-23 | Dyax Corp. | Tie complex binding proteins |
KR20070085236A (ko) | 2004-08-23 | 2007-08-27 | 메다렉스, 인코포레이티드 | 뉴몰리신에 대한 결합원 |
WO2006033386A1 (ja) | 2004-09-22 | 2006-03-30 | Kirin Beer Kabushiki Kaisha | 安定化されたヒトIgG4抗体 |
MX2007003533A (es) | 2004-10-01 | 2007-05-23 | Medarex Inc | Metodos de tratar linfomas cd30 positivas. |
KR100619546B1 (ko) | 2004-10-05 | 2006-09-04 | 아주대학교산학협력단 | 히스톤 h2a 및/또는 h2b에 대한 인간 모노클로날자가항체 및 그 단편 |
CA2590671A1 (en) | 2004-11-18 | 2006-05-26 | Imclone Systems Incorporated | Antibodies against vascular endothelial growth factor receptor-1 |
DE602005022928D1 (de) | 2004-11-30 | 2010-09-23 | Abgenix Inc | Antikörper gegen gpnmb und ihre verwendungen |
EP2284194A1 (en) * | 2004-12-21 | 2011-02-16 | AstraZeneca AB | Antibodies directed to angiopoietin-2 and uses thereof |
TWI306862B (en) | 2005-01-03 | 2009-03-01 | Hoffmann La Roche | Antibodies against il-13 receptor alpha 1 and uses thereof |
WO2006081139A2 (en) | 2005-01-26 | 2006-08-03 | Abgenix, Inc. | Antibodies against interleukin-1 beta |
US8207303B2 (en) | 2005-02-18 | 2012-06-26 | Medarex, Inc. | Monoclonal antibodies against CD30 lacking in fucosyl residues |
NZ560844A (en) | 2005-03-08 | 2008-08-29 | Pharmacia & Upjohn Co Llc | Anti-MAdCAM antibody compositions |
WO2006096489A2 (en) | 2005-03-08 | 2006-09-14 | Pharmacia & Upjohn Company Llc | Anti-m-csf antibody compositions having reduced levels of endotoxin |
DE602005027258D1 (de) | 2005-03-14 | 2011-05-12 | Us Gov Health & Human Serv | Humane monoklonale antikörper gegen hendra- und nipah-viren |
AU2006230413B8 (en) | 2005-03-31 | 2011-01-20 | Xencor, Inc | Fc variants with optimized properties |
WO2006113643A2 (en) | 2005-04-20 | 2006-10-26 | Amgen Fremont Inc. | High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies |
WO2006124269A2 (en) | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
SI1907424T1 (sl) | 2005-07-01 | 2015-12-31 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1) |
EP2311876A3 (en) | 2005-07-28 | 2011-04-27 | Novartis AG | M-CSF-specific monoclonal antibody and uses thereof |
ES2538036T3 (es) | 2005-07-28 | 2015-06-16 | Novartis Ag | Uso de anticuerpo a M-CSF |
PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
PL2447283T3 (pl) * | 2005-09-07 | 2015-12-31 | Amgen Fremont Inc | Ludzkie przeciwciała monoklonalne przeciwko kinazie podobnej do receptora aktywiny-1 (ALK-1) |
ES2592713T3 (es) | 2010-12-20 | 2016-12-01 | Merck Serono S.A. | Derivados de indazolil-triazol como inhibidores de IRAK |
KR101460477B1 (ko) | 2013-06-18 | 2014-11-10 | 주식회사 엘지화학 | 연신 적층체, 박형 편광자의 제조 방법, 이를 이용하여 제조되는 박형 편광자 및 이를 포함하는 편광판 |
JP6319584B2 (ja) | 2015-02-27 | 2018-05-09 | 京セラドキュメントソリューションズ株式会社 | 画像形成システム |
-
2004
- 2004-09-02 AR ARP040103147A patent/AR045563A1/es active IP Right Grant
- 2004-09-07 MY MYPI20043614A patent/MY157376A/en unknown
- 2004-09-08 TW TW093127189A patent/TWI356063B/zh not_active IP Right Cessation
- 2004-09-08 TW TW098140349A patent/TWI365883B/zh not_active IP Right Cessation
- 2004-09-09 KR KR1020067006880A patent/KR100899213B1/ko active IP Right Grant
- 2004-09-09 GB GB0420044A patent/GB2405873A/en not_active Withdrawn
- 2004-09-09 SI SI200432380T patent/SI1670825T1/sl unknown
- 2004-09-09 HN HN2004000356A patent/HN2004000356A/es unknown
- 2004-09-09 NL NL1027009A patent/NL1027009C2/nl not_active IP Right Cessation
- 2004-09-09 KR KR1020087015841A patent/KR100938452B1/ko active IP Right Grant
- 2004-09-09 CA CA2537876A patent/CA2537876C/en not_active Expired - Fee Related
- 2004-09-09 DK DK04809712.5T patent/DK1670825T3/en active
- 2004-09-09 GT GT200400181A patent/GT200400181A/es unknown
- 2004-09-09 AP AP2006003562A patent/AP2006003562A0/xx unknown
- 2004-09-09 GE GEAP20049338A patent/GEP20104922B/en unknown
- 2004-09-09 SG SG200716760-4A patent/SG136945A1/en unknown
- 2004-09-09 AU AU2004275700A patent/AU2004275700B2/en not_active Ceased
- 2004-09-09 PE PE2004000873A patent/PE20050376A1/es active IP Right Grant
- 2004-09-09 ES ES16201588T patent/ES2709700T3/es not_active Expired - Lifetime
- 2004-09-09 EP EP04809712.5A patent/EP1670825B9/en not_active Expired - Lifetime
- 2004-09-09 HU HUE04809712A patent/HUE033708T2/en unknown
- 2004-09-09 UY UY28507A patent/UY28507A1/es not_active Application Discontinuation
- 2004-09-09 MX MX2012002136A patent/MX346194B/es unknown
- 2004-09-09 PA PA20048611701A patent/PA8611701A1/es unknown
- 2004-09-09 CN CN201210133918.4A patent/CN102807617B/zh not_active Expired - Fee Related
- 2004-09-09 CA CA2885172A patent/CA2885172C/en not_active Expired - Fee Related
- 2004-09-09 EP EP16201588.7A patent/EP3170840B1/en not_active Expired - Lifetime
- 2004-09-09 ES ES04809712.5T patent/ES2618526T3/es not_active Expired - Lifetime
- 2004-09-09 US US10/938,353 patent/US7592430B2/en active Active
- 2004-09-09 RS YUP-2006/0171A patent/RS20060171A/sr unknown
- 2004-09-09 NZ NZ584945A patent/NZ584945A/en unknown
- 2004-09-09 JP JP2006526276A patent/JP2007528724A/ja not_active Withdrawn
- 2004-09-09 MX MXPA06002825A patent/MXPA06002825A/es unknown
- 2004-09-09 SG SG2011081270A patent/SG176457A1/en unknown
- 2004-09-09 NZ NZ546369A patent/NZ546369A/en unknown
- 2004-09-09 NZ NZ595450A patent/NZ595450A/xx unknown
- 2004-09-09 BR BRPI0414269A patent/BRPI0414269B8/pt not_active IP Right Cessation
- 2004-09-09 PL PL04809712T patent/PL1670825T3/pl unknown
- 2004-09-09 CN CN200480028051XA patent/CN1863817B/zh not_active Expired - Fee Related
- 2004-09-09 EA EA200600558A patent/EA011669B1/ru not_active IP Right Cessation
- 2004-09-09 PT PT48097125T patent/PT1670825T/pt unknown
- 2004-09-09 WO PCT/US2004/029390 patent/WO2005030124A2/en active Application Filing
- 2004-09-09 UA UAA200603154A patent/UA90457C2/ru unknown
- 2004-09-09 ZA ZA200601969A patent/ZA200601969B/en unknown
-
2006
- 2006-03-01 IL IL174016A patent/IL174016A/en active IP Right Grant
- 2006-03-07 IS IS8342A patent/IS3021B/is unknown
- 2006-03-10 TN TNP2006000080A patent/TNSN06080A1/en unknown
- 2006-03-13 US US11/375,221 patent/US7326414B2/en not_active Expired - Lifetime
- 2006-03-28 CR CR8317A patent/CR8317A/es not_active Application Discontinuation
- 2006-04-07 NO NO20061603A patent/NO343557B1/no not_active IP Right Cessation
- 2006-04-10 MA MA28927A patent/MA28092A1/fr unknown
- 2006-04-10 EC EC2006006497A patent/ECSP066497A/es unknown
- 2006-12-20 HK HK06113986.3A patent/HK1093212A1/xx not_active IP Right Cessation
-
2007
- 2007-08-20 US US11/894,560 patent/US7728113B2/en not_active Expired - Fee Related
- 2007-10-09 JP JP2007263538A patent/JP2008067710A/ja active Pending
-
2010
- 2010-03-29 US US12/748,602 patent/US8188249B2/en not_active Expired - Fee Related
-
2011
- 2011-01-21 JP JP2011010778A patent/JP2011083291A/ja active Pending
-
2012
- 2012-04-27 US US13/458,820 patent/US20120244167A1/en not_active Abandoned
-
2013
- 2013-06-04 HK HK13106536.3A patent/HK1178921A1/xx not_active IP Right Cessation
- 2013-07-16 JP JP2013147604A patent/JP5829653B2/ja not_active Expired - Fee Related
-
2015
- 2015-02-19 IL IL237324A patent/IL237324A0/en active IP Right Grant
- 2015-02-19 IL IL237323A patent/IL237323A0/en active IP Right Grant
- 2015-05-12 JP JP2015097050A patent/JP6106711B2/ja not_active Expired - Fee Related
- 2015-10-27 US US14/923,655 patent/US9718883B2/en not_active Expired - Lifetime
-
2016
- 2016-10-18 JP JP2016204288A patent/JP6412903B2/ja not_active Expired - Fee Related
-
2017
- 2017-06-05 US US15/614,237 patent/US10280219B2/en not_active Expired - Fee Related
-
2019
- 2019-03-15 US US16/354,615 patent/US20190202905A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA90457C2 (ru) | Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms | |
MY145042A (en) | Humanized monoclonal antibodies to hepatocyte growth factor | |
IL178474A0 (en) | Monoclonal antibodies to hepatocyte growth factor and pharmaceutical compositions containing the same | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
GEP20084484B (en) | Antibodies to insulin-like growth factor i receptor | |
WO2005103081A3 (en) | Human monoclonal antibodies against cd20 | |
WO2010054265A3 (en) | Monoclonal antibodies to fibroblast growth factor receptor 2 | |
TN2010000210A1 (en) | Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same | |
IL180364A (en) | Use of antibodies specifically related to amyloid-beta peptide in the manufacture of drugs for the treatment of diseases characterized by amyloid-beta deficiency, pharmaceutical compositions including them and methods for their preparation and methods for use thereof | |
EA201100694A1 (ru) | Антитело к cd38 человека и его применение | |
MXPA06003788A (es) | Anticuerpos completamente humanos contra 4-1bb humano (cd137). | |
WO2010005566A3 (en) | Notch-binding agents and antagonists and methods of use thereof | |
WO2005110474A3 (en) | HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | |
GEP20074222B (en) | Antibodies to cd40 | |
MX2009013656A (es) | Composiciones terapeuticas anti-cd20 y metodos. | |
WO2004094473A3 (en) | Humanized antibodies to interferon alpha receptor-1 (ifnar-1) | |
CA2725873A1 (en) | Monoclonal antibodies to basic fibroblast growth factor | |
TW200517124A (en) | Fully human antibodies against human 4-1BB | |
WO2008100563A3 (en) | Compositions and methods for diagnosing and treating cancer | |
EA201100884A1 (ru) | Моноклональные антитела анти-rhd | |
EP3854875A4 (en) | HUMAN MONOCLONAL ANTIBODY BINDING SPECIFICALLY TO HUMAN HMGB1, AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF ALZHEIMER'S DISEASE CONTAINING SUCH HUMAN MONOCLONAL ANTIBODY | |
WO2008042941A3 (en) | Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease | |
UA98100C2 (ru) | Гуманизированное моноклональное антитело, которое связывается с человеческим nogo и нейтрализует его | |
UA96426C2 (ru) | Выделенное человеческое или гуманизированное антитело, которое специфически связывается с il-13 | |
TW202436354A (zh) | 抗cldn6抗體以及其使用方法 |